Dynamic models for health economic assessments of pertussis vaccines: what goes around comes around.... (Q38068468)

28 August 2017

1 reference

title

Dynamic models for health economic assessments of pertussis vaccines: what goes around comes around.... (English)

1 reference

28 August 2017

4

Maarten J Postma

1 reference

28 August 2017

Mark H Rozenbaum

1

1 reference

28 August 2017

Elisabetta De Cao

series ordinal

2

1 reference

28 August 2017

Tjalke A Westra

series ordinal

3

1 reference

28 August 2017

publication date

1 December 2012

1 reference

Expert Review of Vaccines

28 August 2017

published in

1 reference

28 August 2017

volume

11

1 reference

28 August 2017

issue

12

1 reference

28 August 2017

page(s)

1415-1428

1 reference

Whooping cough--a continuing problem

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Cost-effectiveness analysis of various pertussis vaccination strategies primarily aimed at protecting infants in the Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Rationale for pertussis booster vaccination throughout life in Europe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

How best to estimate the global burden of pertussis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Reemergence of pertussis in the highly vaccinated population of the Netherlands: observations on surveillance data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Transmission of Bordetella pertussis to young infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Infant pertussis: who was the source?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Pertussis of adults and infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

The epidemiology of pertussis: a comparison of the epidemiology of the disease pertussis with the epidemiology of Bordetella pertussis infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

The role of adults in household outbreaks of pertussis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Pertussis sources of infection and routes of transmission in the vaccination era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Resurgence of pertussis in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

A critical literature review of health economic evaluations in pertussis booster vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Clinical and economic assessment of different general population strategies of pertussis vaccine booster regarding number of doses and age of application for reducing whooping cough disease burden: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Conclusions on (cost-)effectiveness of pertussis booster vaccination strategies highly dependent on selections made in evidence review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Modelling the epidemiology of infectious diseases for decision analysis: a primer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Cost-effectiveness of adolescent pertussis vaccination for the Netherlands: using an individual-based dynamic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Adult vaccination strategies for the control of pertussis in the United States: an economic evaluation including the dynamic population effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

An age-structured model for pertussis transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Adolescent and adult pertussis vaccination: computer simulations of five new strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Using computer simulations to compare pertussis vaccination strategies in Australia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Adult pertussis vaccination strategies and their impact on pertussis in the United States: evaluation of routine and targeted (cocoon) strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Simulations of pertussis epidemiology in the United States: effects of adult booster vaccinations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Waning immunity and sub-clinical infection in an epidemic model: implications for pertussis in The Netherlands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

A model based evaluation of the 1996-7 pertussis epidemic in The Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Modelling the impact of extended vaccination strategies on the epidemiology of pertussis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

A model basis for the control of whooping cough.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

A modelling analysis of pertussis transmission and vaccination in Rio de Janeiro, Brazil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Incidence and Reproduction Numbers of Pertussis: Estimates from Serological and Social Contact Data in Five European Countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Estimating the duration of pertussis immunity using epidemiological signatures

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Duration of immunity against pertussis after natural infection or vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Economic analysis of pertussis illness in the Dutch population: implications for current and future vaccination strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Projected cost-effectiveness of new vaccines for adolescents in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Cost effectiveness of pertussis vaccination in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Morbidity of pertussis in adolescents and adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

On discounting of health gains from human papillomavirus vaccination: effects of different approaches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

The incidence of Bordetella pertussis infections estimated in the population from a combination of serological surveys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Using data on social contacts to estimate age-specific transmission parameters for respiratory-spread infectious agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Pertussis vaccines: WHO position paper--recommendations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Cost-effectiveness of varicella vaccination programs: an update of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Seroprevalence of pertussis in The Netherlands: evidence for increased circulation of Bordetella pertussis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Natural immune boosting in pertussis dynamics and the potential for long-term vaccine failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

The case for maternal vaccination against pertussis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Boosting understanding of pertussis outbreaks

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Short-lived immunity against pertussis, age-specific routes of transmission, and the utility of a teenage booster vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Estimating the role of casual contact from the community in transmission of Bordetella pertussis to young infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Social contacts and mixing patterns relevant to the spread of infectious diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Contact network structure explains the changing epidemiology of pertussis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Vaccination and herd immunity: what more do we know?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

"Herd immunity": a rough guide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Incidence of Herpes Zoster, Before and After Varicella‐Vaccination–Associated Decreases in the Incidence of Varicella, 1992–2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Increase in congenital rubella occurrence after immunisation in Greece: retrospective survey and systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Cost-effectiveness estimates for antenatal HIV testing in the Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Cost-effectiveness of rotavirus vaccination in the Netherlands; the results of a consensus model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Comparative review of three cost-effectiveness models for rotavirus vaccines in national immunization programs; a generic approach applied to various regions in the world

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Cost-effectiveness of potential infant vaccination against respiratory syncytial virus infection in The Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Vaccination against colonizing bacteria with multiple serotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Observed differences in invasive pneumococcal disease epidemiology after routine infant vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Effect of reduced-dose schedules with 7-valent pneumococcal conjugate vaccine on nasopharyngeal pneumococcal carriage in children: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Methodological issues and new developments in the economic evaluation of vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Costs and effects of chlamydial screening: dynamic versus static modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Huge impact of assumptions on indirect effects on the cost-effectiveness of routine infant vaccination with 7-valent conjugate vaccine (Prevnar).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

7-Valent pneumococcal conjugate vaccination in England and Wales: is it still beneficial despite high levels of serotype replacement?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Pertussis in The Netherlands: an outbreak despite high levels of immunization with whole-cell vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Pertussis resurgence in Canada largely caused by a cohort effect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Impact of acellular pertussis preschool booster vaccination on disease burden of pertussis in The Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

21 January 2018

Maternal immunization.

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Placental transport of immunoglobulin G.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Bordetella pertussis strains with increased toxin production associated with pertussis resurgence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

21 January 2018

Vaccines in pregnancy

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Neonatal and early life vaccinology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Vaccination in the neonatal period and early infancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Acellular pertussis vaccine use in risk groups (adolescents, pregnant women, newborns and health care workers): a review of evidences and recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Canadian experience with implementation of an acellular pertussis vaccine booster-dose program in adolescents: implications for the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Implementation of cocooning against pertussis in a high-risk population

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Prospective Multinational Study of Pertussis Infection in Hospitalized Infants and Their Household Contacts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Effect of a Prepregnancy Pertussis Booster Dose on Maternal Antibody Titers in Young Infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Source of Infection in Household Transmission of Culture-Confirmed Pertussis in Brazil

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Pertussis in Adolescents and Adults: Should We Accept the Results?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Funding of drugs: do vaccines warrant a different approach?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

The potential cost-effectiveness of acellular pertussis booster vaccination in England and Wales

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Effect of Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization among Immunized and Unimmunized Children in a Community‐Randomized Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Epidemiology of invasive pneumococcal disease in the pre-conjugate vaccine era: England and Wales, 1996–2006

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged ≥65 years in the Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.130

21 January 2018

Identifiers

DOI

10.1586/ERV.12.130

1 reference

28 August 2017

1 reference